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Shedding of Yellow Fever Virus From 
an Imported Case in the Netherlands 
After Travel to Brazil
My V. T. Phan,1 Mariana Mendonca Melo,2 Els van Nood,2 Georgina Aron,1 
Jolanda J. C. Kreeft-Voermans,1 Marion P. G. Koopmans,1 Chantal Reusken,1,a 
Corine H. GeurtsvanKessel,1 and Matthew Cotten1,b
1Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands, 2Department of 
Internal Medicine, Department of Medical Microbiology and Infectious Diseases, Erasmus 
MC, Rotterdam, the Netherlands
We report yellow fever infection in a Dutch traveler returning 
from Brazil. Yellow fever virus (YFV) was identified in serum 
and urine samples over a period of 1  month. Yellow fever 
virus genome sequences from the patient clustered with recent 
Brazilian YFV and showed with limited nucleotide changes 
during the resolving infection.
Keywords.  genomics; vaccination; yellow fever virus.
Yellow fever (YF) is a severe mosquito-borne infection in trop-
ical countries caused by infection with the YF virus (YFV), a 
positive-sense RNA virus in the Flaviviridae family. The disease 
causes 29 000–60 000 deaths annually in Africa and Central and 
South America [1]. Despite the availability of an effective YF 
vaccine since 1939 [2], vaccine uptake is variable and vaccine 
supply in some regions is insufficient [3]. This, combined with 
incomplete vector control and human mobility, has resulted 
in recent outbreaks in Brazil [4] and several areas in Africa 
(Angola, Nigeria, South Sudan, Democratic Republic of Congo) 
[5]. In addition to the local consequences, increased infections 
can also lead to YF in returning travelers, and this is impor-
tant to monitor [6–9]. In this study, we present a case of YF in 
an unvaccinated Dutch traveler returning from Brazil in early 
2018 and describe YFV genomic sequences obtained directly 
from multiple longitudinal clinical samples. (The YFV genomic 
sequences described here have been deposited in GenBank, 
accession numbers MK760660–MK760666.) To obtain insight 
into the kinetics of shedding of arboviral infections and to op-
timize diagnostic algorithms, serial samples were collected 
until the patient cleared the infection, allowing assessment of 
intrapatient variability in the virus as the infection was cleared. 
The patient consented to this study.
PATIENTS AND METHODS
A previously healthy 46-year-old traveler returned to the 
Netherlands on January 8, 2018 after a 3-week stay in 
Mairiporã, Brazil (Table 1). The patient began to show symp-
toms on January 7, 2018 and presented at the hospital on 
January 11 (day 5 of symptoms) with fever (38°C), myalgia, 
headache, nausea, vomiting, and lower back pain. Laboratory 
testing revealed increased transaminases with aspartate trans-
aminase 2298 U/L (standard reference [SR] <35 U/L), alanine 
aminotransferase 3147 U/L (SR  <45 U/L), gamma-glutamyl 
transferase 86 U/L (SR <55 U/L), and an increased lactate de-
hydrogenase (LDH) 1545 (SR  <248 U/L) with a mild throm-
bocytopenia of 146 × 109/L (SR 150–370/L). Leukocytes were 
normal and C-reactive protein was not increased. The patient 
had never received a YFV vaccination.
Given the clinical presentation and the concurrent outbreak 
of YF in Brazil during the patient’s traveling period, YF was 
suspected and the presence of YFV was confirmed by real-
time reverse-transcription polymerase chain reaction (PCR) 
on blood and urine samples. Tests for other possible agents or 
diseases (human immunodeficiency virus, viral hepatitis vir-
uses, dengue virus, chikungunya virus, Zika virus, leptospi-
rosis, malaria, and typhus) were negative. Furthermore, YFV 
was successfully isolated, and a full genome sequence was 
obtained from Vero cell culture established from a urine sample 
(see below). The liver enzymes and LDH levels returned to the 
normal range, and the patient recovered and was discharged on 
January 15, 2018. Of interest, YFV nucleic acid was detected in 
blood, urine, and semen samples as described in Table  1, in-
cluding full-genome sequences from multiple blood and urine 
samples. The declining YFV levels in the blood and urine, as 
well as the serum anti-YFV immunoglobulin (Ig)G and IgM 
values, were consistent with a resolving YFV infection (Table 1). 
Semen samples showed very low levels of YFV (high threshold 
concentration values of 33.5 and 34.8), and all attempts to se-
quence or culture YFV from semen failed. However, a full YFV 
genome was obtained from a urine sample 4 days after release 
of the patient from the hospital and approximately 2 weeks after 
symptom onset.
Due to the low levels of YFV in the later samples, sequencing 
primers to increase sensitivity were used to generate overlapping 
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Figure 1. Genomic analyses of the reported yellow fever virus (YFV) genomes. (A) Maximum-likelihood phylogenetic tree. Yellow fever virus genomes from the case were 
aligned with complete YFV sequences available from GenBank, manually checked, and trimmed to complete open reading frame. A maximum-likelihood phylogenetic tree 
was constructed using the sequence alignment in RAxML [14], with 100 pseudoreplicates, under the GTR + Γ 4 model of evolution, which was determined as the best-fitted 
model using IQ-TREE [15] under the Akaike Information Criterion. The resultant tree was visualized in FigTree v1.4.3 [16]. The phylogenetic tree was mid-point rooted for 
clarity, and only bootstrap values for major clades were shown. The scale bar is given in units of number of nucleotide (nt) substitutions per site (subs/site). The Brazilian out-
break 2017 clade (light green box), YFV genomes from the case (blue box covering the red lineage), the YFV vaccine strain (blue node). Genotypes of YFV clades are indicated 
as follows: SA1 = South America I genotype, SA2 = South American II genotype, Wafr = West Africa genotype, and Eafr = East Africa genotype. (A_inset) Nucleotide differ-
ences across the reported YFV genomes. All assembled YFV genomes from this case were aligned and compared against the earliest genome obtained (t146a163; January 11, 
2018; serum sample). Nucleotide differences were indicated by vertical lines, and gaps in the sequence were indicated by gray bars. Each row represents a YFV genome from 
the patient, and the panel above shows the positions of YFV coding regions. (B) Minor variant analysis. Positions in the YFV genome with minor (less than majority) variants 
in the short-read sequencing data. Quality-controlled and adapter and primer-trimmed data were mapped to the consensus genome. The number of reads with nonmajority 
nucleotides at each position were determined using BWA mapping followed by visualization of minor variant counts. Only positions with at least 30-fold read coverage and 
Phred values >30 were reported. The upper insert shows the positions of the YFV protein coding regions. The main panel indicated positions with minor variant content. Each 
marker represents a sample/genome, and the markers are colored by the number of the 7 samples that showed variation at that site, with orange, red, and dark red indicating 
4, 5, or 6 of the 7 samples showing minor variants at that site. The dark red markers at 7623 indicate a site where 6 of the 7 samples showed variation, and the heights of 
the markers indicate the level of each sample’s minor variant content. (C) Decline in minor variant content over the course of the infection. The minor variant content was 
presented by each sample organized by day of infection (except for the cell culture sample). Each marker (color-coded by position) represents the minor variant content at that 
position. In both B and C, fraction 0.1 (10% of the reads at that position, the significance cutoff) is marked with a gray dotted line.
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1200–1500 nucleotide amplicons spanning the YFV genome. 
Yellow fever virus genome primers were designed from all 
publicly available YFV genome sequences (N  =  72 genomes, 
March 2017), all potential primer targets in the sequences 
were identified (calculated melting temperature of 48°C, GC 
content ≤40% absence of homopolymers), and highly con-
served targets were selected at the appropriate positions in 
the genome. Primer sequences and further details are avail-
able (see https://github.com/mlcotten/Yellow_fever_virus). 
Next-generation sequencing was performed directly on clin-
ical samples (blood, urine, and semen) as follows. Nucleic acid 
was extracted with Roche MagNa Pure extraction kit (Roche, 
Mannheim, Germany) and subjected to reverse transcription 
and PCR amplified using YFV genome primers. Polymerase 
chain reaction products were pooled, enzymatically sheared 
to 400-base pair fragments, converted to Ion Torrent libraries, 
and sequenced (Ion Torrent S5XL) yielding 2–4 million reads/
sample. Short reads were trimmed to remove read-terminal 
primers and trimmed from the 3’ end to a median read Phred 
score <25 and de novo assembled using SPAdes v.3.11.0 [10]. 
Yellow fever virus contigs were identified by protein homology 
to a Flaviviridae protein database. Partial but overlapping ge-
nomic contigs were further assembled, and ambiguous nucleo-
tide positions were resolved by counting sequence motifs in the 
short-read data.
Six full YFV genome sequences were obtained from patient 
samples over an 8-day period, and 1 genome sequence was 
obtained from passage 3 Vero cell culture (initiated from the 
12-Jan-18 urine sample). All YFV genome sequences were in 
the South America I (SA1) clade of YFV (Figure 1A) and were 
most closely related to Brazilian YFV sequences from 2017 
(Figure  1B), consistent with the patient’s travel history. The 
Yellow Fever Virus Typing Tool [11] assigned the novel gen-
omes to SA1, supporting the phylogenetic analysis.
RESULTS AND DISCUSSION
Few changes were observed in viral genome sequences during 
the infection (Figure 1 A, inset). Two nucleotide changes in the 
NS4B coding region did not alter the NS4B protein. Several 
positions in the 3’ terminal repeat sequences [12] showed C to 
T changes (Figure 1 A, inset). The cell culture passaged virus 
genome t146a335 showed 1 nucleotide difference from the ge-
nome derived directly from the January 12, 2018 urine sample, 
resulting in a lysine to glutamic acid change in the NS4B pro-
tein. We examined levels of nonconsensus minor variant 
sequences across the course of infection (Figure 1 B). Multiple 
positions in the genome showed variation in at least 4 of the 
samples (Figure  1 B, in orange, red, or dark red; consistent 
with variant persistence during the infection); however, only 
7 positions showed positions with greater 10% minor variant 
(Figure 1 B, above the gray dotted line). The day1_urine sample 
showed slightly higher variant levels than the day1_serum 
sample (Figure 1 C). The minor variant content declined as the 
infection was cleared with day4_urine showing only 3 positions 
with minor variants above 10% and day9_urine showing only 1 
site with minor variants above 10%, and no consistently fixed 
changes. The culture-derived virus showed the lowest level of 
minor variants (Figure 1 C).
CONCLUSIONS
The YFV genomes from this case clustered with recent 
sequences from Brazil, consistent with the patient’s travel 
history and ruling out other geographical sources of the in-
fection. Yellow fever virus RNA was detectable for 14  days 
postsymptom onset. Serial samples from the patient clearing 
infection indicated that variant sites were present and persisted 
across multiple time points, but the total number of variants 
and variant sites declined as the infection was resolved. No 
changes were observed in the encoded viral proteins in vivo, 
and only a single amino change was observed after 3 passages 
of the virus in vitro. To our knowledge, viral nucleotide vari-
ants across a resolving YFV infection has not been examined 
in this detail before, and we conclude that the variant nucleo-
tide differences were unlikely to provide an advantage for the 
virus and disappeared late in the infection. The functional im-
pact of the single amino acid change observed in cell culture 
passage virus is unknown and should be investigated. In re-
cent studies, YFV has been detected in urine and semen sam-
ples [12, 13]. The data reported here further demonstrate the 
utility of urine samples as a diagnostic sample and an easily 
obtained, noninvasive source of readily sequenced YFV. It is 
notable that at all time points in which both sample types were 
measured, the quantity of YFV in urine was greater than in 
blood supporting urine as a convenient and sensitive source 
for YFV diagnostics. The YFV amplicon primers and method 
provide a useful tool for generating YFV genomic sequences. 
Finally, the case provides an important message for vigilance 
for YF by infectious disease clinicians and alert for travelers 
to organize YFV vaccination before traveling to regions with 
endemic or ongoing YF infections.
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